Comments
Laurus Labs on Friday informed the exchanges that it has received Establishment Inspection Report from the US Food and Drug Administraion for its finished dosage formulations (FDF) and active pharmaceutical ingredients at Atchutapuram, Visakhapatnam. The inspection was completed in May 2017, it said. Besides, BGV Hamburg (German Regulatory Authority) and WHO inspections also completed their inspections with no critical or major observations. Laurus Labs’ shares closed at ₹549.80, almost flat, on the BSE.
Cadila Healthcare on Friday informed the exchanges that it has received approvals from the USFDA for two products. The company said it has received final nod for modafinil tablets and tentative nod for solifenacin succinate tablets. in strengths of 5 mg and 10 mg. Both the drugs will be manufactured at the group’s formulations manufacturing facility at Pharma SEZ, Ahmedabad. Modafinil tablets are said to improve wakefulness in adult patients with a kind of sleep disorder. Solifenacin succinate tablets are prescribed for the treatment of overactive bladder associated with symptoms of urinary incontinence and urinary frequency. Shares of Cadila Healthcare closed at ₹479.05 on the BSE, down 0.36 per cent.
Shipping Corporation of India has taken physical delivery of a secondhand very large gas carrier (VLGC) of 53,503 DWT capacity. The stock of Shipping Corporation gained 0.27 per cent at ₹92.45 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.